Evidence map›Paper›PMID 36001250›Full record

ReviewHeart failure reviews2023

"Digital biomarkers" in preclinical heart failure models - a further step towards improved translational research.

Alexander Schmidt, Jakob Balitzki, Ljubica Grmaca, Julia Vogel, Philip Boehme, Katharina Boden, Jörg Hüser, Hubert Truebel, Thomas Mondritzki

Abstract readReview
In one paragraph

Review in Heart failure reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander Schmidt *Bayer AG, BAG-PH-RD-RED-TA1-CPM-CPM2, Building 0520, 42096, Wuppertal, Germany.
Jakob Balitzki *Bayer AG, BAG-PH-RD-RED-TA1-CPM-CPM2, Building 0520, 42096, Wuppertal, Germany.
Ljubica GrmacaBayer AG, BAG-PH-RD-RED-TA1-CPM-CPM2, Building 0520, 42096, Wuppertal, Germany.
Julia VogelBayer AG, BAG-PH-RD-RED-TA1-CPM-CPM2, Building 0520, 42096, Wuppertal, Germany.
Philip BoehmeUniversity of Witten/Herdecke, Witten, Germany.
Katharina BodenUniversity of Witten/Herdecke, Witten, Germany.
Jörg HüserBayer AG, BAG-PH-RD-RED-TA1-CPM-CPM2, Building 0520, 42096, Wuppertal, Germany.
Hubert TruebelUniversity of Witten/Herdecke, Witten, Germany.
Thomas MondritzkiBayer AG, BAG-PH-RD-RED-TA1-CPM-CPM2, Building 0520, 42096, Wuppertal, Germany. thomas.mondritzki@bayer.com.ORCID 0000-0003-0162-773X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innovations in the development of novel heart failure therapies are essential to further increase the predictive value of early research findings. Animal models are still playing a pivotal role in 'translational research'. In recent years, the transferability from animal studies has been more and more critically discussed due to persistent high attrition rates in clinical trials. However, there is an increasing trend to implement mobile health devices in preclinical studies. These devices can increase the predictive value of animal models by providing more accurate and translatable data and protect from confounding factors. This review outlines the current prevalence and opportunities of these techniques in preclinical heart failure research studies to accelerate the integration of these important tools. A literature screening for preclinical heart failure studies in large animals implementing telemetry devices over the last decade was performed. Twelve out of 43 publications were included. A variety of different hemodynamic and cardiac parameters can be recorded in conscious state by means of telemetry devices in both, the animal model and the patient. The measurement quality is consistently rated as valid and robust. Mobile health technologies functioning as digital biomarkers represent a more predictive approach compared to the traditionally used invasive measurement techniques, due to the possibility of continuous data collection in the conscious animal. Furthermore, they help to implement the 3R concept (reduction, refinement, replacement) in animal research. Despite this, the use of these techniques in preclinical research has been restrained to date.

Indexed as

Heart FailureAnimalsBiomarkersHeartHumansModels, AnimalTelemetryBiomarkersAnimal modelHeart failureMobile healthTelemetryTranslational research

Identifiers

PMID36001250
PMCPMC9902409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.